Sachs Associates

🌟🚀 Spotlight on Tomorrow's Innovators! Join us for the 'Early-Stage Ventures Panel: Picking Winners' at the #Sachs_BEF on September 26th, 2024, at the Mövenpick Hotel Basel. Learn how investors identify and support the most promising early-stage companies in the biotech sector. Co-Chaired by: Marie Schroeder, Vice President, Novo Holdings A/S Shelley Margetson, Managing Partner, V-Bio Ventures BV Panellists: Clare Wareing, Founder & CEO, Cumulus Oncology Edward Van Wezel, Managing Partner, BGV (BioGeneration Ventures) Michael Altorfer, CEO, Swiss Biotech Association Michael R Huebner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC Stephan Emmerth, Director, BaseLaunch This panel will provide an insider's view on the strategies used by seasoned investors to scout and select early-stage biotech ventures poised for success. Engage with top venture capitalists and angel investors as they share their experiences, criteria, and insights on making the right bets in the rapidly evolving biotech landscape. Don’t miss this opportunity to gain valuable insights and strategies that could drive the next big breakthrough in biotech. Secure your spot today at www.sachsforum.com/24bef and join us, both #inperson & #online, during the Sachs Autumn Life Sciences Week. #BiotechInvestment #VentureCapital #EarlyStageInvesting #StartupSuccess #BiotechStartups #Innovation #Sachs_BEF #SALSW

Stalicla, founded in 2017, a precision neuro clinical stage company, has raised $80m with Novartis, Pitcted, Edmond de Rothschild, and SPRIM as shareholders. Preparing for a $65m Series C to support Phase 2 trials and advance its neuro precision pipeline. Meet STALICLA SA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

inHEART is a deep-tech healthcare startup based in France and the US. The company develops web-based SaaS solutions for cardiologists by utilizing AI. inHEART leverages cardiac images and electrocardiograms uploaded by the physician to deliver a digital twin of the patient’s heart for cardiac arrhythmia treatment support and prevention/screening for cardiac diseases. The company has gathered substantial clinical evidence and received a Class II MDR CE mark and FDA 510(k) clearance. inHEART started commercializing its SaaS solution in 2022 and is rapidly growing its user base in Europe and the US, now available in over 140 hospitals. The company uses its vast amount of annotated clinical data to train powerful predictive AI software to prevent and screen for sudden cardiac death, cardio-embolic stroke, and heart failure. These SaaS solutions will be released in several phases, starting in 2025. Meet inHEART @ #Sachs_HTIF More Info @ https://lnkd.in/df5auS9k #HealthTech #DigitalHealth #MedTech #HealthTechInnovation #BigData #AI #HealthTechForum #PharmaTechnology #MedicalDevices #HealthcareTechnology #HealthTechInvestment #SALSW

🔬🛡️ Advancing the Frontier of Cancer Treatment! Join us for the 'Immuno-Oncology Progress Panel' at the #Sachs_BEF on September 26th, 2024, at the Mövenpick Hotel Basel. Explore the latest breakthroughs and developments in immuno-oncology that are transforming cancer care. Co-Chaired by: Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG Francois Thomas, Operating Partner, Quadrille Capital Panellists: Alex Blyth, CEO, LIfT BioSciences Ltd. Alfred Slanetz, Founder & CEO, Geneius Biotechnology, Inc. Aram Mangasarian, CEO, TME Pharma Eric Halioua, President & CEO, PDC*line Pharma SA Paul Bravetti, CEO, Brenus Pharma This panel will delve into the cutting-edge advancements in immuno-oncology, highlighting innovative therapies that harness the body's immune system to fight cancer. Engage with leading experts as they discuss new therapeutic strategies, clinical trials results, and the future potential of immuno-oncology treatments. Don’t miss this opportunity to gain in-depth insights and network with pioneers in the field. Secure your spot today at www.sachsforum.com/24bef and join us, both #inperson & #online, during the Sachs Autumn Life Sciences Week. #ImmunoOncology #CancerResearch #OncologyInnovation #Biotech #MedicalResearch #CancerTherapy #Sachs_BEF #SALSW

Frank is the Chief Commercial Officer of Partex N.V. group, a 250+ people AI based asset manager with strong healthcare AI, patient data, validation, blockchain and incubation capabilities. He is currently based in Cham, Switzerland. Before joining Partex, he served as the Global Head of Alliance Management and European Head Business Development at Everest Medicines, a company with a clinical portfolio of products predominantly focusing on China. He used to be the VP, Head of R&D Alliance Management & Head Research Transactions, and later VP, Alliance Management, General Medicines, Emerging Markets and Consumer Health Care at Sanofi. During his time at Sanofi, he has also been the Risk Management leader of the Strategy & Business Development group and a permanent member of the Sanofi Corporate Risk Committee. Furthermore, he has been an Advisory Board member of ASAP. Prior to joining Sanofi, he was working in a variety of Partnering functions for Roche in China and Switzerland. Before switching to Partnering, he served in various Research positions for Roche in Switzerland and for Boehringer Mannheim in Germany. He holds a PhD in Chemistry from TU Munich (MPI Biochemistry, Martinsried, lab of Nobel laureate Robert Huber). Meet Frank Grams @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

At Lifespin we are pioneering precision health through the integration of AI-enhanced metabolomic measurements and digital twin technology. Lifespin’s cutting-edge platform merges advanced nuclear magnetic resonance (NMR), artificial intelligence, deep data analytics, and cloud technologies to establish a new frontier in personalized medicine. This revolutionary combination not only redefines existing benchmarks in oncology and other known medical conditions but also ventures into previously unexplored territories, such as specific neurological disorders. Our proprietary AI transformer and foundation model are instrumental in deciphering the intricate relationships between clinical metabolomics and health conditions. By generating a novel metabolomic information layer, Lifespin’s platform facilitates transformative applications in preventive medicine, complex disease diagnostics, treatment monitoring, and patient stratification. The core of our innovation lies in our ability to capture and analyze individual metabolomes accurately, assessing hundreds of metabolite concentrations through a single NMR measurement. This presentation will highlight real-world applications from ongoing clinical studies in inflammatory, oncological, and neurological conditions, showcasing how our technology enables affordable, large-scale health screenings. With a self-evolving database encompassing over 250,000 human datasets — including healthy baselines and data from more than 700 disease phenotypes — Lifespin is at the vanguard of delivering personalized health solutions that significantly reduce healthcare costs and enhance accessibility on a global scale. Join us to explore how Lifespin is setting new standards in the healthcare industry, moving towards a future where healthcare is more proactive, personalized, and preventative. Explainer Video: https://lnkd.in/dKbNk452 Meet lifespin GmbH @ #Sachs_HTIF More Info @ https://lnkd.in/df5auS9k #HealthTech #DigitalHealth #MedTech #HealthTechInnovation #BigData #AI #HealthTechForum #PharmaTechnology #MedicalDevices #HealthcareTechnology #HealthTechInvestment #SALSW

💼🚀 Explore the Dynamics of Biotech Financing! Join us for the 'Venture & Private Equity Roundtable' at the #Sachs_BEF on September 25th, 2024, at the Mövenpick Hotel Basel. Dive into the world of venture capital and private equity that fuels the biotech industry’s growth and innovation. Co-Chaired by: Marianne Uteng, Managing Director, Novartis Venture Fund Steven Dickman, CEO, CBT Advisors Panellists: Cindy Daniel, Head of Unit - Life Sciences & Healthcare, European Investment Fund (EIF) Hakan Goker, Managing Director, M Ventures Hubert Birner, Managing Partner, TVM Capital Life Science Magne Stoknes, Principal, Novo Holdings A/S Matthieu Coutet, Partner, Sofinnova Partners This roundtable will feature an in-depth discussion with leading venture capitalists and private equity investors who are shaping the future of biotech. Gain insights into investment trends, strategies for navigating the funding landscape, and perspectives on upcoming market opportunities in the biotech sector. Don't miss this chance to connect with industry leaders and financial experts. Secure your spot today at www.sachsforum.com/24bef and be part of this enlightening discussion, both #InPerson & #Online, during the Sachs Autumn Life Sciences Week. #BiotechVC #PrivateEquity #BiotechFunding #InvestmentTrends #LifeSciences #VentureCapital #Biotech #SALSW

Seth is responsible for Cullgen Inc. corporate strategy, business development, communications, and commercial development functions. He brings over 30 years of professional experience in the life sciences industry, including 25 years of broad business development and licensing experience at Eli Lilly & Co., Vical, Senomyx, Allylix / Evolva, Ginkgo Bioworks, and his own consulting firm, Life Sciences Partnering Strategies, LLC. During the course of his career, Seth has been responsible for the signature of numerous licensing deals cumulatively valued at over $5 billion. In 2023, Seth was recognized with a Deal of Distinction Award by the Licensing Executives Society. In addition to his strong licensing experience in the human health field, he has also completed numerous transactions in the consumer products and synthetic biology fields. Seth earned his MBA from the Kelley School of Business at Indiana University and his MS in Chemical Engineering from The Ohio State University. Seth is also a certified Licensing Professional (CLP) and Licensed Professional Engineer (PE). When not pursuing professional activities, Seth is an avid cyclist, chess player, and pilot of remote controlled aircraft. Meet Seth Goldblum @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Eyal Lifschitz is an entrepreneur and investor with years of experience in establishing and managing life science companies and their business development efforts. Lifschitz serves as the Co-founder and Managing General Partner of Peregrine Ventures, a global life science venture capital fund dedicated to improving patients' quality of life by investing in and supporting life changing healthcare opportunities. In this role, he oversees all daily operations and mentors entrepreneurs on their journeys to bring innovative medical technologies to market. On behalf of Peregrine, Lifschitz serves on the boards of Momentis Surgical, Nectin Therapeutics, Restore Medical, Kahr Medical, Cordio Medical, Raziel Therapeutics and others. Previously, Lifschitz was involved as a founder and a manager in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, BioControl, and as a director of Given Imaging (NASDAQ: GIVN). Lifschitz serves as Chairman in the Israeli Early-Stage Investors Association (IEI) & Technology Incubator Forum (ITIF) which promotes Israeli high-tech ventures both domestically and abroad. Lifschitz is also a Founder and Chairman of GamVeGam, a non-for-profit cooperation between the Israeli Ministry of Education and the Israeli high-tech industry which aims to encourage high-tech professionals to become teachers in public schools, and he also serves on the Board of Trustee at Bar Ilan University. Meet Eyal Lifschitz @ #Sachs_HTIF More Info @ https://lnkd.in/df5auS9k #HealthTech #DigitalHealth #MedTech #HealthTechInnovation #BigData #AI #HealthTechForum #PharmaTechnology #MedicalDevices #HealthcareTechnology #HealthTechInvestment #SALSW

💼🌐 Navigating Investment Landscapes in HealthTech! Join us for the ‘Corporate & Financial Investors Roundtable’ at the #Sachs_HTIF on September 24th, 2024, at the Mövenpick Hotel Basel. Engage with top investors and financial experts to discuss strategies for thriving in the evolving HealthTech sector. Co-Chaired by: Christian Kannemeier, Sr. Investment Manager, HTGF | High-Tech Gründerfonds Diana Saraceni, Co-Founder & General Partner, Panakes Partners SGR SpA Panellists: Beatriz Volckaert Almansa, Senior Associate - Venture Investments, Philips Ventures Eric de La Fortelle, Managing Partner, Cathay Health Eyal Lifschitz, Co-Founder & General Managing Partner, Peregrine Ventures Jean-Francois Rivassou, Partner, Kurma Partners Stephan Wehrli, Investment Principal & Partner, Zühlke Group Ventures AG This roundtable brings together prominent corporate and financial investors to explore the current and future investment landscapes in HealthTech. Participants will gain insights into funding trends, investment challenges, and opportunities within digital health, MedTech, and beyond. This is an essential discussion for anyone involved in investing or seeking investment in the HealthTech industry. Don’t miss this opportunity to connect with leading minds in investment. Secure your spot today at www.sachsforum.com/11htif and join us, both #inperson & #online, during the Sachs Autumn Life Sciences Week. #HealthTechInvesting #FinancialInvestors #CorporateInvestors #InvestmentStrategies #HealthTech #DigitalHealth #MedTech #SALSW